Skip to main content

Biophytis S.A. (BPTS)

NASDAQ: BPTS · Delayed Price · USD
8.40
+0.45 (5.64%)
After-hours:Sep 20, 2021 4:51 PM EDT
7.95
-0.62 (-7.21%)
At close: Sep 20, 4:00 PM
Market Cap96.38M
Revenue (ttm)n/a
Net Income (ttm)-20.80M
Shares Out12.21M
EPS (ttm)-2.84
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,733
Open8.38
Previous Close8.57
Day's Range7.90 - 8.00
52-Week Range7.90 - 18.50
Beta1.13
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About BPTS

Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases and the treatment of severe respiratory failure in patients suffering from COVID-19. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead ...

IndustryBiotechnology
IPO DateFeb 10, 2021
CEOStanislas Veillet
Employees25
Stock ExchangeNASDAQ
Ticker SymbolBPTS
Full Company Profile

Financial Performance

Financial numbers in millions EURFinancial Statements

News

Biophytis Reports H1 2021 Financial Results and Provides Business Update

PARIS and CAMBRIDGE, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeut...

4 days ago - GlobeNewsWire

Biophytis Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase...

PARIS and CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeut...

6 days ago - GlobeNewsWire

Biophytis to Attend Key Upcoming Investor Events and Industry Conferences

PARIS and CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeut...

1 week ago - GlobeNewsWire

Biophytis Leadership is Reinforced With New Chief Medical Officer Appointment

PARIS and CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeut...

1 week ago - GlobeNewsWire

DMC Recommends Biophytis Continue Sarconeos COVID-19 Study

The Data Monitoring Committee (DMC) has recommended Biophytis SA (NASDAQ: BPTS) to continue patient recruitment into part 2 of Phase 2-3 COVA Study in COVID-19, with the protocol unmodified after review...

1 month ago - Benzinga

Biophytis Receives Favorable Recommendation From Data Monitoring Committee (DMC) Based on Safety Analysis of Sarconeo...

PARIS and CAMBRIDGE, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeuti...

1 month ago - GlobeNewsWire

Biophytis Announces the Issue of 4,950,000 New Shares in a Capital Increase Reserved for NEGMA and the Performance of...

PARIS and CAMBRIDGE, Mass., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”), a clinical-stage biotechnology company focused ...

1 month ago - GlobeNewsWire

Biophytis Stock Gains As Sarconeos High Dose Improves Gait Speed Versus Placebo In Patients With Muscle Loss Due To A...

Biophytis SA (NASDAQ: BPTS) has announced top-line results of the SARA-INT phase 2 clinical study with Sarconeos (BIO101) in sarcopenia patients. Sarcopenia is a condition characterized by loss of skele...

1 month ago - Benzinga

Biophytis Announces Top Line Results of SARA-INT Phase 2 Study With Sarconeos (BIO101) in Sarcopenia

PARIS and CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”) is a clinical-stage biotechnology company focuse...

1 month ago - GlobeNewsWire

Judgment Rendered on July 16, 2021 in the Proceedings Between Biophytis and Negma Group Ltd by the Execution Judge Fr...

PARIS and CAMBRIDGE, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused ...

2 months ago - GlobeNewsWire

Biophytis Stock Is Trading Higher On Encouraging Preclinical Data From COVID-19 Study With Sarconeos

Biophytis SA (NASDAQ: BPTS) announced new positive preclinical data on Sarconeos (BIO101) in hamsters infected with SARS-CoV-2, the virus responsible for COVID-19. The data will be presented at the Euro...

2 months ago - Benzinga

Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021

PARIS and CAMBRIDGE, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”), a clinical-stage biotechnology company focused...

2 months ago - GlobeNewsWire

Biophytis Reinforces Leadership Teams with Three Senior Appointments

PARIS and CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”), a clinical-stage biotechnology company focused...

2 months ago - GlobeNewsWire

Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milest...

PARIS and CAMBRIDGE Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”), a clinical-stage biotechnology company focused ...

2 months ago - GlobeNewsWire

Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021

PARIS and CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”),a clinical-stage biotechnology company focused ...

2 months ago - GlobeNewsWire

Biophytis announces new convertible bond financing for up to €32 million with Atlas and drawing of 2 tranches under t...

PARIS and Cambridge, Mass., June 19, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused...

3 months ago - GlobeNewsWire

BIOPHYTIS - Results of the Combined General Meeting on May 10, 2021

All ordinary and extraordinary resolutions have been adopted All ordinary and extraordinary resolutions have been adopted

4 months ago - GlobeNewsWire

Biophytis – Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareh...

PARIS and CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at slo...

4 months ago - GlobeNewsWire

Biophytis Receives €980,000 DeepTech Funding from BPI France for the development of Macuneos (BIO201) in Dry AMD

PARIS and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at slo...

4 months ago - GlobeNewsWire

Biophytis Gives Operational Perspectives on its Sarconeos (BIO101) Ahead of its Upcoming AGM on April 26, 2021

PARIS and CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that are aim...

4 months ago - GlobeNewsWire

BIOPHYTIS Identifies False Report Regarding COVA study

PARIS and CAMBRIDGE, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeut...

5 months ago - GlobeNewsWire

BIOPHYTIS Gives Updates on its Phase 2-3 COVA Study on COVID-19

PARIS and CAMBRIDGE, Mass., March 22, 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“BIOPHYTIS” or the “company”), a clinical-stage biotechnology company focuse...

5 months ago - GlobeNewsWire

Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis Against Negma Group Ltd

PARIS and CAMBRIDGE, Mass., March 19, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused...

6 months ago - GlobeNewsWire

Biophytis' Combined Annual General Meeting Will Take Place on April 26, 2021 behind closed doors

Legally required documents for shareholders' votes are available on Biophytis website

6 months ago - GlobeNewsWire

Biophytis Reports 2020 Full Year Results

PARIS and CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused ...

6 months ago - GlobeNewsWire